Goldberg Alan B, Mazur Wojciech, Kalra Dinesh K
Department of Internal Medicine, Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA.
The Christ Hospital, Cincinnati, Ohio, USA.
Cardiovasc Diagn Ther. 2017 Aug;7(4):405-417. doi: 10.21037/cdt.2017.04.11.
Pulmonary hypertension (PH), defined as the elevation of mean pulmonary arterial pressure (mPAP) above 25 mmHg, has numerous causes, which the World Health Organization (WHO) has divided into five distinct categories based upon the underlying mechanism of action. This review will explore the pathophysiology, diagnostic testing, and treatment of PH. Identification of PH depends on a strong clinical suspicion, a detailed history, and a thorough physical exam. We review the evidence supporting experimental and clinical laboratory parameters for diagnosis and monitoring of PH. Transthoracic echocardiogram (TTE) is the initial screening test of choice. This review will detail specific echocardiographic techniques for the assessment and classification of PH. Furthermore, the importance of advanced imaging, including computed tomography (CT) and magnetic resonance imagining (MRI) is explored. New developments in pharmacology, percutaneous intervention, and surgical approaches are summarized. Finally, we will address the tools available to predict morbidity and mortality.
肺动脉高压(PH)定义为平均肺动脉压(mPAP)高于25 mmHg,其病因众多,世界卫生组织(WHO)根据潜在作用机制将其分为五个不同类别。本综述将探讨PH的病理生理学、诊断检测及治疗。PH的识别依赖于强烈的临床怀疑、详细的病史及全面的体格检查。我们回顾支持用于PH诊断和监测的实验及临床实验室参数的证据。经胸超声心动图(TTE)是首选的初始筛查检查。本综述将详细介绍用于PH评估和分类的特定超声心动图技术。此外,还探讨了包括计算机断层扫描(CT)和磁共振成像(MRI)在内的高级成像的重要性。总结了药理学、经皮介入及手术方法的新进展。最后,我们将讨论可用于预测发病率和死亡率的工具。